Possible to Reduce Treatment Burden in HER2-Positive Breast Cancer?
This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer.
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses the idea of using clinical features to reduce treatment burden in patients with HER2-positive breast cancer.
While biomarkers that could help clinicians more appropriately personalize treatments for patients with HER2-positive disease are still in development, trials using clinical features have already explored different ways to reduce treatment toxicity.
Tolaney discusses one such trial, the APT (Adjuvant Paclitaxel and Trastuzumab) trial, which examined a less toxic regimen for patients with small HER2-positive tumors: 12 weeks of weekly paclitaxel (80 mg/m2) plus weekly trastuzumab (2 mg/kg), followed by 9 months of trastuzumab (6 mg/kg) every 3 weeks.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
